Results 31 - 40 of 208 : Previous 1 2 3 4 5 6 7 8 9 Next
Don't Worry About Vytorin's Cancer Risk
Congress' ramblings are much ado about nothing.
PDL BioPharma's Partnership Makes Sense
Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
Exelixis Gets Ready to Partner Up
The company is looking for some friends to help develop its drugs.
Despite his tough talk, Icahn will likely complete a buyout of ImClone.
It's hard to argue with across-the-board success.
Will a shift in strategy turn the drugmaker around?
The drugmaker posts strong earnings, but the good times may not last.
Drug Duo SEAS Disappointment -- Again
Merck and Schering continue their string of bad luck.
Pivotal clinical trial results for a top drug are finally within sight.
A British Fool sees weakness, but also great opportunities.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK